This is a challenging question where little data exist to support a good conclusion. In real world situations, patients with cytopenias and suggestion of TR-MN warrant aggressive antibodies find yourself deciding which is the "best of class" in its nature.  John

I agree with Dr. @John C. Byrd that few data exist in this space. There is a theoretical risk of harm that using myeloid growth factors in the setting of active aggressive myeloid malignancies could stimulate the blast populations, but the data to support this is thin and some limited data sugg...